ALLURION TECHNOLOGIES, INC. ALUR-WT Financial Statement Data


2025 Q2

Submissions

Field Row 1
adsh 0000950170-25-072662
cik 1964979
name ALLURION TECHNOLOGIES, INC.
sic 3841
countryba US
stprba MA
cityba NATICK
zipba 01760
bas1 11 HURON DR STE 200
bas2
baph 508-647-4000
countryma US
stprma MA
cityma NATICK
zipma 01760
mas1 11 HURON DR STE 200
mas2
countryinc US
stprinc DE
ein 000000000
former ALLURION TECHNOLOGIES HOLDINGS, INC.
changed 20230207
afs 4-NON
wksi 0
fye 1231
form 10-Q
period 20250331
fy 2025
fp Q1
filed 20250515
accepted 2025-05-15 16:16:00.0
prevrpt 0
detail 1
instance alur-20250331_htm.xml
nciks 1
aciks

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
cik Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings.
name Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date.
sic Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business.
countryba The ISO 3166-1 country of the registrant's business address.
stprba The state or province of the registrant’s business address, if field countryba is US or CA.
cityba The city of the registrant's business address.
zipba The zip code of the registrant’s business address.
bas1 The first line of the street of the registrant’s business address.
bas2 The second line of the street of the registrant’s business address.
baph The phone number of the registrant’s business address.
countryma The ISO 3166-1 country of the registrant's mailing address.
stprma The state or province of the registrant’s mailing address, if field countryma is US or CA.
cityma The city of the registrant's mailing address.
zipma The zip code of the registrant’s mailing address.
mas1 The first line of the street of the registrant’s mailing address.
mas2 The second line of the street of the registrant’s mailing address.
countryinc The ISO 3166-1 country of incorporation for the registrant.
stprinc The state or province of incorporation for the registrant, if countryinc is US or CA.
ein Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States.
former Most recent former name of the registrant, if any.
changed Date of change from the former name, if any.
afs Filer status with the SEC at the time of submission:
1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned.
wksi Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement.
fye Fiscal Year End Date, rounded to nearest month-end.
form The submission type of the registrant’s filing.
period Balance Sheet Date, rounded to nearest month-end.
fy Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8).
fp Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year.
filed The date of the registrant’s filing with the Commission.
accepted The acceptance date and time of the registrant’s filing with the Commission.
prevrpt Previous Report – TRUE indicates that the submission information was subsequently amended.
detail TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount).
instance The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol.
nciks Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing.
aciks Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information.

Numbers

adsh ddate tag value uom qtrs version segments coreg footnote
0000950170-25-072662 20231231 Additional Paid In Capital 100000.0000 USD 0 us-gaap/2024 Credit Facility= Chardan Equity Facility; Type Of Arrangement= Chef Purchase Agreement;
0000950170-25-072662 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect -8353000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Common Stock Shares Issued 5963549.0000 shares 0 us-gaap/2024
0000950170-25-072662 20230731 Common Stock Shares Outstanding 215468.0000 shares 0 us-gaap/2024 Type Of Arrangement= Pipe Investors;
0000950170-25-072662 20250331 Common Stock Shares Outstanding 5963549.0000 shares 0 us-gaap/2024
0000950170-25-072662 20241231 Common Stock Value 3000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Common Stock Value 5000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Comprehensive Income Net Of Tax 2939000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Depreciation And Amortization 64000.0000 USD 1 us-gaap/2024 Income Statement Location= General And Administrative Expense;
0000950170-25-072662 20250331 Depreciation And Amortization 203000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Increase Decrease In Inventories -22000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Inventory Write Down 25000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Issuance Of Shares Common Stock In Connection With R T W Private Placement Net Of Issuance Costs 841751.0000 shares 1 0000950170-25-072662 Equity Components= Common Stock;
0000950170-25-072662 20250331 Issuance Of Value Common Stock In Connection With Public Offering Net Of Issuance Costs 1000.0000 USD 1 0000950170-25-072662 Equity Components= Common Stock; Subsidiary Sale Of Stock= January Public Offering;
0000950170-25-072662 20250331 Liabilities And Stockholders Equity 38414000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20241231 Liabilities Current 18863000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20240331 Net Cash Provided By Used In Financing Activities 387000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Net Cash Provided By Used In Operating Activities -8636000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Non Cash Lease Expense 212000.0000 USD 1 0000950170-25-072662
0000950170-25-072662 20240331 Operating Expenses 18256000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20241231 Operating Lease Right Of Use Asset 2079000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20241231 Preferred Stock Value USD 0 us-gaap/2024
0000950170-25-072662 20250331 Profit Loss 7379000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Research And Development Expense 429000.0000 USD 1 us-gaap/2024 Income Statement Location= Product Development;
0000950170-25-072662 20241231 Restricted Cash 339000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Revenue From Contract With Customer Excluding Assessed Tax 5580000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Share Based Compensation 500000.0000 USD 1 us-gaap/2024 Award Type= Employee Stock Option;
0000950170-25-072662 20230731 Warrants And Rights Outstanding 13800000.0000 USD 0 us-gaap/2024 Class Of Warrant Or Right= Public Warrants;
0000950170-25-072662 20240331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 552000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20241231 Allowance For Doubtful Accounts Premiums And Other Receivables 6701000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Amortization Of Issuance Costs Associated With Warrants 1137000.0000 USD 1 0000950170-25-072662
0000950170-25-072662 20250331 Assets 38414000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20241231 Assets Current 27156000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Assets Current 33166000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20241231 Business Combination Contingent Consideration Liability Noncurrent 1090000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Common Stock Shares Authorized 1000000000.0000 shares 0 us-gaap/2024
0000950170-25-072662 20230731 Common Stock Shares Outstanding 15508.0000 shares 0 us-gaap/2024 Type Of Arrangement= Side Letter Termination Shares;
0000950170-25-072662 20240331 Cost Of Revenue 2520000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Fair Value Adjustment Of Earn Out Liabilities 14190000.0000 USD 1 0000950170-25-072662
0000950170-25-072662 20250331 Increase Decrease In Accounts Payable -2409000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Increase Decrease In Accounts Receivable 883000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Increase Decrease In Accrued Liabilities And Other Operating Liabilities -989000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Weighted Average Number Of Shares Outstanding Basic 1911181.0000 shares 1 us-gaap/2024
0000950170-25-072662 20250331 Increase Decrease In Accrued Liabilities And Other Operating Liabilities -1468000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Interest Paid Net 1831000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Inventory Write Down 209000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Issuance Of Value Common Stock In Connection With Public Offering Net Of Issuance Costs 588000.0000 USD 1 0000950170-25-072662 Equity Components= Additional Paid In Capital; Subsidiary Sale Of Stock= February Public Offering And Leavitt Private Placement;
0000950170-25-072662 20241231 Liabilities 110791000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Operating Expenses 11443000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment Attributable To Parent -1420000.0000 USD 1 us-gaap/2024 Debt Instrument= Rtw Convertible Notes;
0000950170-25-072662 20250228 Other Nonoperating Income Expense -200000.0000 USD 0 us-gaap/2024 Subsidiary Sale Of Stock= February Warrant Repricing;
0000950170-25-072662 20250331 Other Nonoperating Income Expense 1100000.0000 USD 1 us-gaap/2024 Longterm Debt Type= Rtw Convertible Notes;
0000950170-25-072662 20250331 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0000950170-25-072662 20240331 Research And Development Expense 3271000.0000 USD 1 us-gaap/2024 Income Statement Location= Clinical Trials And Medical Affairs;
0000950170-25-072662 20240331 Selling And Marketing Expense 6145000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Share Based Compensation 897000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Stockholders Equity -207213000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0000950170-25-072662 20230731 Stock Issued During Period Shares New Issues 10000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock; Type Of Arrangement= Amended And Restated Rtw Side Letter;
0000950170-25-072662 20240331 Stock Issued During Period Shares New Issues 5730.0000 shares 1 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-072662 20250331 Stock Issued During Period Shares Restricted Stock Award Gross 3505.0000 shares 1 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-072662 20240331 Stock Issued During Period Value Stock Options Exercised 9000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Stock Issued During Period Value Stock Options Exercised 9000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000950170-25-072662 20241231 Warrants And Rights Outstanding 4567000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20241231 Accounts Payable Current 6572000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Additional Paid In Capital 157843000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20241231 Assets 32813000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20241231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 15718000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20240331 Change In Fair Value Of Warrant Liabilities -3131000.0000 USD 1 0000950170-25-072662
0000950170-25-072662 20250331 Change In Fair Value Of Warrant Liabilities -5669000.0000 USD 1 0000950170-25-072662
0000950170-25-072662 20240331 Changes In Fair Value Of Debt 0.0000 USD 1 0000950170-25-072662
0000950170-25-072662 20250331 Commitments And Contingencies USD 0 us-gaap/2024
0000950170-25-072662 20230731 Common Stock Shares Outstanding 206628.0000 shares 0 us-gaap/2024 Type Of Arrangement= Compute Health;
0000950170-25-072662 20231231 Common Stock Shares Outstanding 379299.0000 shares 0 us-gaap/2024 Credit Facility= Chardan Equity Facility; Equity Components= Common Stock; Type Of Arrangement= Chef Purchase Agreement;
0000950170-25-072662 20241231 Common Stock Shares Outstanding 25.0000 shares 0 us-gaap/2024 Class Of Stock= Reverse Stock Split; Equity Components= Common Stock;
0000950170-25-072662 20240331 Depreciation And Amortization 201000.0000 USD 1 us-gaap/2024 Income Statement Location= Cost Of Sales;
0000950170-25-072662 20250331 Earnings Per Share Diluted 0.2000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Fair Value Adjustment Of Earn Out Liabilities 910000.0000 USD 1 0000950170-25-072662
0000950170-25-072662 20240630 General And Administrative Expense 100000.0000 USD 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Subsidiary Sale Of Stock= July Two Thousand Twenty Four Private Placement Warrants;
0000950170-25-072662 20240331 Gross Profit 6866000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Increase Decrease In Prepaid Deferred Expense And Other Assets -244000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Operating Income Loss -11390000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20241231 Operating Lease Liability Current 869000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment Attributable To Parent 2200000.0000 USD 1 us-gaap/2024 Debt Instrument= P I P E Conversion Option;
0000950170-25-072662 20240331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent -2200000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20241231 Other Liabilities Noncurrent 17000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20241231 Preferred Stock Shares Authorized 100000000.0000 shares 0 us-gaap/2024
0000950170-25-072662 20250331 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2024
0000950170-25-072662 20240331 Proceeds From Equity Line Financing 378000.0000 USD 1 0000950170-25-072662
0000950170-25-072662 20240331 Research And Development Expense 747000.0000 USD 1 us-gaap/2024 Income Statement Location= Digital;
0000950170-25-072662 20250331 Research And Development Expense 2624000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Research And Development Expense 529000.0000 USD 1 us-gaap/2024 Income Statement Location= Quality And Regulatory;
0000950170-25-072662 20250331 Revenue From Contract With Customer Excluding Assessed Tax 4150000.0000 USD 1 us-gaap/2024 Geographical= All Other Countries;
0000950170-25-072662 20250331 Revenue From Contract With Customer Excluding Assessed Tax 749000.0000 USD 1 us-gaap/2024 Geographical= E S;
0000950170-25-072662 20231231 Shares Outstanding 1907529.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-072662 20231231 Stockholders Equity 143010000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000950170-25-072662 20240831 Stockholders Equity 50000000.0000 USD 0 us-gaap/2024 Range= Maximum;
0000950170-25-072662 20241231 Stockholders Equity 3000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-072662 20250331 Stockholders Equity 157843000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000950170-25-072662 20250331 Stockholders Equity -231568000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0000950170-25-072662 20230731 Stock Issued During Period Shares New Issues 38000.0000 shares 0 us-gaap/2024 Type Of Arrangement= Fortress Credit Agreement;
0000950170-25-072662 20250331 Weighted Average Number Of Diluted Shares Outstanding 6017438.0000 shares 1 us-gaap/2024
0000950170-25-072662 20250331 Accounts Receivable Net Current 8309000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Business Combination Contingent Consideration Liability Noncurrent 180000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20240331 Change In Unrealized Gain Loss On Fair Value Hedging Instruments1 -62000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024 Class Of Stock= Common Class A;
0000950170-25-072662 20230731 Common Stock Shares Outstanding 1892058.0000 shares 0 us-gaap/2024
0000950170-25-072662 20230731 Common Stock Shares Outstanding 132049.0000 shares 0 us-gaap/2024 Type Of Arrangement= Convertible Note Holders;
0000950170-25-072662 20230731 Common Stock Shares Outstanding 76000.0000 shares 0 us-gaap/2024 Type Of Arrangement= Rtw And Fortress;
0000950170-25-072662 20240331 Comprehensive Income Net Of Tax 3386000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Depreciation And Amortization 367000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Depreciation And Amortization 8000.0000 USD 1 us-gaap/2024 Income Statement Location= General And Administrative Expense;
0000950170-25-072662 20240331 Earnings Per Share Basic 2.9200 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Earnings Per Share Diluted 2.7800 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Gross Profit 4161000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 5662000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Interest Expense Nonoperating 1931000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Issuance Of Common Stock For Exercise Of Warrants Shares 6.0000 shares 1 0000950170-25-072662 Equity Components= Common Stock;
0000950170-25-072662 20250331 Issuance Of Shares Common Stock In Connection With Public Offering Net Of Issuance Costs 1167686.0000 shares 1 0000950170-25-072662 Equity Components= Common Stock; Subsidiary Sale Of Stock= February Public Offering And Leavitt Private Placement;
0000950170-25-072662 20250331 Issuance Of Value Common Stock In Connection With Public Offering Net Of Issuance Costs 1262000.0000 USD 1 0000950170-25-072662 Equity Components= Additional Paid In Capital; Subsidiary Sale Of Stock= January Public Offering;
0000950170-25-072662 20241231 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0000950170-25-072662 20241231 Accounts Payable And Other Accrued Liabilities Current 11422000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Accounts Payable And Other Accrued Liabilities Current 10092000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Accumulated Other Comprehensive Income Loss Net Of Tax 3930000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20230731 Additional Paid In Capital 15200000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 20748000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20231231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 38421000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 20748000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Change In Fair Value Of Revenue Interest Financing Through Oci -3020000.0000 USD 1 0000950170-25-072662
0000950170-25-072662 20250331 Change In Fair Value Of Share Obligation 700000.0000 USD 1 0000950170-25-072662
0000950170-25-072662 20241231 Commitments And Contingencies USD 0 us-gaap/2024
0000950170-25-072662 20250331 Cost Of Revenue 1419000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Depreciation And Amortization 53000.0000 USD 1 us-gaap/2024 Income Statement Location= Selling And Marketing Expense;
0000950170-25-072662 20250331 Depreciation And Amortization 55000.0000 USD 1 us-gaap/2024 Income Statement Location= Research And Development Expense;
0000950170-25-072662 20240331 Fair Value Adjustment Of Warrants -3131000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Foreign Currency Transaction Gain Loss Before Tax 335000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Increase Decrease In Accounts Receivable -1673000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Increase Decrease In Prepaid Deferred Expense And Other Assets -147000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20241231 Inventory Net 3400000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Issuance Of Shares Common Stock In Connection With Public Offering Net Of Issuance Costs 1240000.0000 shares 1 0000950170-25-072662 Equity Components= Common Stock; Subsidiary Sale Of Stock= January Public Offering;
0000950170-25-072662 20250331 Liabilities 108204000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Net Cash Provided By Used In Operating Activities -9469000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Net Income Loss 5586000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Net Income Loss 7379000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0000950170-25-072662 20240331 Non Cash Interest Expense 315000.0000 USD 1 0000950170-25-072662
0000950170-25-072662 20240331 Non Cash Lease Expense 199000.0000 USD 1 0000950170-25-072662
0000950170-25-072662 20250331 Operating Lease Liability Noncurrent 1186000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment Attributable To Parent -3020000.0000 USD 1 us-gaap/2024 Debt Instrument= Revenue Interest Financing Due;
0000950170-25-072662 20250331 Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment Attributable To Parent -1400000.0000 USD 1 us-gaap/2024 Longterm Debt Type= Rtw Convertible Notes;
0000950170-25-072662 20240331 Other Nonoperating Income Expense 172000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Profit Loss 5586000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Property Plant And Equipment Net 2297000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20240331 Research And Development Expense 662000.0000 USD 1 us-gaap/2024 Income Statement Location= Quality And Regulatory;
0000950170-25-072662 20240331 Revenue From Contract With Customer Excluding Assessed Tax 1112000.0000 USD 1 us-gaap/2024 Geographical= E S;
0000950170-25-072662 20240331 Revenue From Contract With Customer Excluding Assessed Tax 1256000.0000 USD 1 us-gaap/2024 Geographical= G B;
0000950170-25-072662 20240331 Shares Outstanding 1915956.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-072662 20241231 Shares Outstanding 2710607.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-072662 20231231 Stockholders Equity -70487000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20231231 Stockholders Equity -700000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000950170-25-072662 20240331 Stockholders Equity 2000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-072662 20241231 Stockholders Equity 8370000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000950170-25-072662 20250331 Weighted Average Number Of Shares Outstanding Basic 4778542.0000 shares 1 us-gaap/2024
0000950170-25-072662 20241231 Liabilities And Stockholders Equity 32813000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20240331 Net Cash Provided By Used In Investing Activities -104000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Net Income Loss 5586000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0000950170-25-072662 20240331 Nonoperating Income Expense 17052000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Operating Lease Right Of Use Asset 1870000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20240331 Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment Attributable To Parent -2200000.0000 USD 1 us-gaap/2024 Debt Instrument= Revenue Interest Financing Due;
0000950170-25-072662 20240331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent -2200000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000950170-25-072662 20250331 Other Nonoperating Income Expense -213000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20241231 Preferred Stock Shares Issued 0.0000 shares 0 us-gaap/2024
0000950170-25-072662 20250331 Prepaid Expense And Other Assets Current 1097000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20241231 Retained Earnings Accumulated Deficit -238947000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20240331 Revenue From Contract With Customer Excluding Assessed Tax 1671000.0000 USD 1 us-gaap/2024 Geographical= F R;
0000950170-25-072662 20250331 Share Based Compensation 400000.0000 USD 1 us-gaap/2024 Award Type= Restricted Stock Units R S U;
0000950170-25-072662 20231231 Stockholders Equity 2000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-072662 20240331 Stockholders Equity -66162000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20230731 Stock Issued During Period Shares New Issues 28000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock; Type Of Arrangement= Backstop Agreement;
0000950170-25-072662 20230731 Stock Issued During Period Shares New Issues 15508.0000 shares 0 us-gaap/2024 Equity Components= Common Stock; Type Of Arrangement= H V L Termination Agreement;
0000950170-25-072662 20250331 Stock Issued During Period Shares Stock Options Exercised 0.0000 shares 1 us-gaap/2024 Plan Name= Two Thousand And Ten Stock Option Plan Two Thousand And Twenty Stock Option Plan Two Thousand And Twenty Three Stock Option And Incentive Plan;
0000950170-25-072662 20231231 Stock Issued During Period Value New Issues 100000000.0000 USD 0 us-gaap/2024 Credit Facility= Chardan Equity Facility; Type Of Arrangement= Chef Purchase Agreement;
0000950170-25-072662 20250331 Warrants And Rights Outstanding 13206720.0000 USD 0 us-gaap/2024 Subsidiary Sale Of Stock= Public Warrant;
0000950170-25-072662 20250331 Accounts Payable Current 4976000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20240331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 552000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000950170-25-072662 20241231 Cash And Cash Equivalents At Carrying Value 15379000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20241231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 15718000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 30068000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect 5030000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Change In Fair Value Of Revenue Interest Financing Through Oci -2200000.0000 USD 1 0000950170-25-072662
0000950170-25-072662 20250331 Changes In Fair Value Of Revenue Interest Financing And Pipe Conversion Option 2220000.0000 USD 1 0000950170-25-072662
0000950170-25-072662 20250331 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0000950170-25-072662 20241231 Common Stock Shares Issued 2710607.0000 shares 0 us-gaap/2024
0000950170-25-072662 20230731 Common Stock Shares Outstanding 130509.0000 shares 0 us-gaap/2024 Type Of Arrangement= Compute Health Sponsor Shares;
0000950170-25-072662 20250331 Convertible Long Term Notes Payable 30960000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Depreciation And Amortization 127000.0000 USD 1 us-gaap/2024 Income Statement Location= Cost Of Sales;
0000950170-25-072662 20240331 General And Administrative Expense 6386000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Increase Decrease In Accounts Payable 1551000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Increase Decrease In Inventories -330000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Issuance Of Value Common Stock In Connection With Public Offering Net Of Issuance Costs 1000.0000 USD 1 0000950170-25-072662 Equity Components= Common Stock; Subsidiary Sale Of Stock= February Public Offering And Leavitt Private Placement;
0000950170-25-072662 20250331 Issuance Of Value Common Stock In Connection With Public Offering Net Of Issuance Costs 589000.0000 USD 1 0000950170-25-072662 Subsidiary Sale Of Stock= February Public Offering And Leavitt Private Placement;
0000950170-25-072662 20250331 Nonoperating Income Expense 14756000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Operating Lease Liability Current 829000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent -4440000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Preferred Stock Value USD 0 us-gaap/2024
0000950170-25-072662 20250331 Proceeds From Issuance Or Sale Of Equity 14499000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Provision For Doubtful Accounts 72000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Research And Development Expense 5725000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Research And Development Expense 1045000.0000 USD 1 us-gaap/2024 Income Statement Location= Product Development;
0000950170-25-072662 20250331 Research And Development Expense 1264000.0000 USD 1 us-gaap/2024 Income Statement Location= Clinical Trials And Medical Affairs;
0000950170-25-072662 20250331 Retained Earnings Accumulated Deficit -231568000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20240331 Revenue From Contract With Customer Excluding Assessed Tax 9386000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Revenue From Contract With Customer Excluding Assessed Tax 0.0000 USD 1 us-gaap/2024 Geographical= E G;
0000950170-25-072662 20250331 Revenue From Contract With Customer Excluding Assessed Tax 600000.0000 USD 1 us-gaap/2024 Geographical= E G;
0000950170-25-072662 20250331 Revenue From Contract With Customer Excluding Assessed Tax 0.0000 USD 1 us-gaap/2024 Geographical= F R;
0000950170-25-072662 20231231 Stockholders Equity -212799000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0000950170-25-072662 20241231 Stockholders Equity -77978000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20240331 Changes In Fair Value Of Revenue Interest Financing And Pipe Conversion Option 1490000.0000 USD 1 0000950170-25-072662
0000950170-25-072662 20250331 Common Stock Shares Issued 0.0000 shares 0 us-gaap/2024 Plan Name= Two Thousand And Twenty Three Employee Stock Purchase Plan;
0000950170-25-072662 20241231 Accumulated Other Comprehensive Income Loss Net Of Tax 8370000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 897000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20230731 Business Combination Contingent Consideration Liability Noncurrent 53000000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20240331 Capital Expenditures Incurred But Not Yet Paid 73000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Cash And Cash Equivalents At Carrying Value 20408000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20230731 Common Stock Shares Outstanding 1115896.0000 shares 0 us-gaap/2024 Type Of Arrangement= Legacy Allurion Equityholders;
0000950170-25-072662 20241231 Common Stock Shares Outstanding 2710607.0000 shares 0 us-gaap/2024
0000950170-25-072662 20240331 Depreciation And Amortization 49000.0000 USD 1 us-gaap/2024 Income Statement Location= Research And Development Expense;
0000950170-25-072662 20250331 Depreciation And Amortization 13000.0000 USD 1 us-gaap/2024 Income Statement Location= Selling And Marketing Expense;
0000950170-25-072662 20250331 Earnings Per Share Basic 1.5400 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Fair Value Adjustment Of Debt -6170000.0000 USD 1 0000950170-25-072662
0000950170-25-072662 20240331 Foreign Currency Transaction Gain Loss Before Tax -314000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Income Tax Expense Benefit 76000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Issuance Of Value Common Stock In Connection With Public Offering Net Of Issuance Costs 1263000.0000 USD 1 0000950170-25-072662 Subsidiary Sale Of Stock= January Public Offering;
0000950170-25-072662 20250331 Net Cash Provided By Used In Financing Activities 14499000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20241231 Operating Lease Liability Noncurrent 1344000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Other Assets Noncurrent 1081000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250131 Other Nonoperating Income Expense -500000.0000 USD 0 us-gaap/2024 Subsidiary Sale Of Stock= January Warrant Repricing;
0000950170-25-072662 20240331 Payments To Acquire Property Plant And Equipment 104000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240630 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Subsidiary Sale Of Stock= Private Placement With R T W;
0000950170-25-072662 20250331 Preferred Stock Shares Authorized 100000000.0000 shares 0 us-gaap/2024
0000950170-25-072662 20241231 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2024
0000950170-25-072662 20241231 Prepaid Expense And Other Assets Current 1243000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20240331 Proceeds From Option And Warrant Exercises 9000.0000 USD 1 0000950170-25-072662
0000950170-25-072662 20250331 Restricted Cash 340000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20240331 Revenue From Contract With Customer Excluding Assessed Tax 5347000.0000 USD 1 us-gaap/2024 Geographical= All Other Countries;
0000950170-25-072662 20250331 Revenue From Contract With Customer Excluding Assessed Tax 81000.0000 USD 1 us-gaap/2024 Geographical= G B;
0000950170-25-072662 20250331 Revenue Interest Financing Liability Noncurrent 50000000.0000 USD 0 0000950170-25-072662
0000950170-25-072662 20250331 Selling And Marketing Expense 3621000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Share Based Compensation 552000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Shares Outstanding 5963549.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-072662 20240331 Stockholders Equity 143949000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000950170-25-072662 20241231 Stockholders Equity 152596000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000950170-25-072662 20250331 Stockholders Equity 3930000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000950170-25-072662 20250331 Stockholders Equity 5000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-072662 20240331 Stock Issued During Period Shares Restricted Stock Award Gross 2505.0000 shares 1 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-072662 20250331 Warrants And Rights Outstanding 9264000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20240331 Weighted Average Number Of Diluted Shares Outstanding 1967885.0000 shares 1 us-gaap/2024
0000950170-25-072662 20241231 Accounts Receivable Net Current 7134000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20241231 Additional Paid In Capital 152596000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 897000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000950170-25-072662 20250331 Allowance For Doubtful Accounts Premiums And Other Receivables 6455000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Change In Fair Value Of Rtw Convertible Notes Through Oci -1420000.0000 USD 1 0000950170-25-072662
0000950170-25-072662 20250331 Changes In Fair Value Of Debt -6170000.0000 USD 1 0000950170-25-072662
0000950170-25-072662 20241231 Common Stock Shares Authorized 1000000000.0000 shares 0 us-gaap/2024
0000950170-25-072662 20250331 Common Stock Shares Issued 64000.0000 shares 0 us-gaap/2024 Plan Name= Two Thousand And Twenty Three Employee Stock Purchase Plan; Range= Maximum;
0000950170-25-072662 20241231 Convertible Long Term Notes Payable 35710000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction 921000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Fair Value Adjustment Of Warrants -5669000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 General And Administrative Expense 5198000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 7474000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Income Tax Expense Benefit 95000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Increase Decrease In Operating Lease Liability -238000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Increase Decrease In Operating Lease Liability -199000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Inventory Net 3352000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Issuance Of Common Stock In Connection With R T W Private Placement Net Of Issuance Costs 2500000.0000 USD 1 0000950170-25-072662
0000950170-25-072662 20250331 Issuance Of Common Stock In Connection With R T W Private Placement Net Of Issuance Costs 2500000.0000 USD 1 0000950170-25-072662 Equity Components= Additional Paid In Capital;
0000950170-25-072662 20250331 Liabilities Current 15897000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Net Income Loss 7379000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20250331 Operating Income Loss -7282000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20241231 Other Assets Noncurrent 1109000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent -4440000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000950170-25-072662 20250331 Other Liabilities Noncurrent 717000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20241231 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Preferred Stock Shares Issued 0.0000 shares 0 us-gaap/2024
0000950170-25-072662 20250331 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock;
0000950170-25-072662 20240630 Proceeds From Issuance Or Sale Of Equity 1000000.0000 USD 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Subsidiary Sale Of Stock= July Two Thousand Twenty Four Private Placement Warrants;
0000950170-25-072662 20241231 Property Plant And Equipment Net 2469000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20250331 Research And Development Expense 402000.0000 USD 1 us-gaap/2024 Income Statement Location= Digital;
0000950170-25-072662 20241231 Revenue Interest Financing Liability Noncurrent 49200000.0000 USD 0 0000950170-25-072662
0000950170-25-072662 20240331 Stockholders Equity -2900000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000950170-25-072662 20241231 Stockholders Equity -238947000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0000950170-25-072662 20250331 Stockholders Equity -69790000.0000 USD 0 us-gaap/2024
0000950170-25-072662 20240331 Stock Issued During Period Shares Stock Options Exercised 186.0000 shares 1 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-072662 20240331 Stock Issued During Period Value New Issues 378000.0000 USD 1 us-gaap/2024
0000950170-25-072662 20240331 Stock Issued During Period Value New Issues 378000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
ddate The end date for the data value, rounded to the nearest month end.
qtrs The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value.
uom The unit of measure for the value.
segments Tags used to represent axis and member reporting.
coreg If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity.
value The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point.
footnote The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank.

Tags

tag version custom abstract datatype iord crdr tlabel doc
Increase Decrease In Accounts Receivable us-gaap/2024 0 0 monetary D C Increase (Decrease) in Accounts Receivable The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
Stock Issued During Period Value Stock Options Exercised us-gaap/2024 0 0 monetary D C Stock Issued During Period, Value, Stock Options Exercised Value of stock issued as a result of the exercise of stock options.
Assets Current us-gaap/2024 0 0 monetary I D Assets, Current Amount of asset recognized for present right to economic benefit, classified as current.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 0 0 monetary I D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Operating Lease Liability Current us-gaap/2024 0 0 monetary I C Operating Lease, Liability, Current Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
Revenue From Contract With Customer Excluding Assessed Tax us-gaap/2024 0 0 monetary D C Revenue from Contract with Customer, Excluding Assessed Tax Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Changes In Fair Value Of Revenue Interest Financing And Pipe Conversion Option 0000950170-25-072662 1 0 monetary D C Changes In Fair Value Of Revenue Interest Financing And Conversion Option Changes in fair value of revenue interest financing and PIPE conversion option.
Allowance For Doubtful Accounts Premiums And Other Receivables us-gaap/2024 0 0 monetary I C Allowance for Doubtful Accounts, Premiums and Other Receivables The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.
Depreciation And Amortization us-gaap/2024 0 0 monetary D D Depreciation, Depletion and Amortization, Nonproduction The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
Payments To Acquire Property Plant And Equipment us-gaap/2024 0 0 monetary D C Payments to Acquire Property, Plant, and Equipment The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
Proceeds From Issuance Or Sale Of Equity us-gaap/2024 0 0 monetary D D Proceeds from Issuance or Sale of Equity The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
Stock Issued During Period Shares Restricted Stock Award Gross us-gaap/2024 0 0 shares D Stock Issued During Period, Shares, Restricted Stock Award, Gross Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.
Comprehensive Income Net Of Tax us-gaap/2024 0 0 monetary D C Comprehensive Income (Loss), Net of Tax, Attributable to Parent Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Convertible Long Term Notes Payable us-gaap/2024 0 0 monetary I C Convertible Notes Payable, Noncurrent Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.
Issuance Of Common Stock In Connection With R T W Private Placement Net Of Issuance Costs 0000950170-25-072662 1 0 monetary D C Issuance of Common Stock in Connection with RTW Private Placement, Net of Issuance Costs Issuance of common stock in connection with RTW private placement, net of issuance costs.
Proceeds From Option And Warrant Exercises 0000950170-25-072662 1 0 monetary D D Proceeds from Option and Warrant Exercises Proceeds from option and warrant exercises.
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest us-gaap/2024 0 0 monetary D C Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Liabilities us-gaap/2024 0 0 monetary I C Liabilities Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.
Liabilities And Stockholders Equity us-gaap/2024 0 0 monetary I C Liabilities and Equity Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Retained Earnings Accumulated Deficit us-gaap/2024 0 0 monetary I C Retained Earnings (Accumulated Deficit) Amount of accumulated undistributed earnings (deficit).
Stockholders Equity us-gaap/2024 0 0 monetary I C Equity, Attributable to Parent Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
Accounts Receivable Net Current us-gaap/2024 0 0 monetary I D Accounts Receivable, after Allowance for Credit Loss, Current Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Additional Paid In Capital us-gaap/2024 0 0 monetary I C Additional Paid in Capital Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.
Common Stock Par Or Stated Value Per Share us-gaap/2024 0 0 perShare I Common Stock, Par or Stated Value Per Share Face amount or stated value per share of common stock.
Common Stock Shares Outstanding us-gaap/2024 0 0 shares I Common Stock, Shares, Outstanding Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
Income Tax Expense Benefit us-gaap/2024 0 0 monetary D D Income Tax Expense (Benefit) Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Net Income Loss us-gaap/2024 0 0 monetary D C Net Income (Loss) Attributable to Parent The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 0 0 shares D Weighted Average Number of Shares Outstanding, Diluted The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Amortization Of Issuance Costs Associated With Warrants 0000950170-25-072662 1 0 monetary D D Amortization Of Issuance Costs Associated With Warrants Amortization of issuance costs associated with warrants.
Fair Value Adjustment Of Earn Out Liabilities 0000950170-25-072662 1 0 monetary D C Fair Value Adjustment of Earn Out Liabilities Fair value adjustment of earn-out liabilities.
Issuance Of Shares Common Stock In Connection With R T W Private Placement Net Of Issuance Costs 0000950170-25-072662 1 0 shares D Issuance of Shares Common Stock in Connection with RTW Private Placement, Net of Issuance Costs Issuance of shares common stock in connection with RTW private placement, net of issuance costs,
Non Cash Lease Expense 0000950170-25-072662 1 0 monetary D D Non-Cash Lease Expense Non-cash lease expense.
Accumulated Other Comprehensive Income Loss Net Of Tax us-gaap/2024 0 0 monetary I C Accumulated Other Comprehensive Income (Loss), Net of Tax Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.
Assets us-gaap/2024 0 0 monetary I D Assets Amount of asset recognized for present right to economic benefit.
Common Stock Shares Issued us-gaap/2024 0 0 shares I Common Stock, Shares, Issued Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
Earnings Per Share Diluted us-gaap/2024 0 0 perShare D Earnings Per Share, Diluted The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
Gross Profit us-gaap/2024 0 0 monetary D C Gross Profit Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
Operating Lease Right Of Use Asset us-gaap/2024 0 0 monetary I D Operating Lease, Right-of-Use Asset Amount of lessee's right to use underlying asset under operating lease.
Other Assets Noncurrent us-gaap/2024 0 0 monetary I D Other Assets, Noncurrent Amount of noncurrent assets classified as other.
Selling And Marketing Expense us-gaap/2024 0 0 monetary D D Selling and Marketing Expense The aggregate total amount of expenses directly related to the marketing or selling of products or services.
Business Combination Contingent Consideration Liability Noncurrent us-gaap/2024 0 0 monetary I C Business Combination, Contingent Consideration, Liability, Noncurrent Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.
Change In Fair Value Of Warrant Liabilities 0000950170-25-072662 1 0 monetary D D Change in Fair Value of Warrant Liabilities Change in fair value of warrant liabilities.
Changes In Fair Value Of Debt 0000950170-25-072662 1 0 monetary D D Changes In Fair Value Of Debt Changes in fair value of debt.
Issuance Of Shares Common Stock In Connection With Public Offering Net Of Issuance Costs 0000950170-25-072662 1 0 shares D Issuance Of Shares Common Stock in Connection with Public Offering, Net Of Issuance Costs Issuance of shares common stock in connection with public offering, net of issuance costs.
Non Cash Interest Expense 0000950170-25-072662 1 0 monetary D D Noncash Interest Expense Noncash interest expense.
Revenue Interest Financing Liability Noncurrent 0000950170-25-072662 1 0 monetary I C Revenue Interest Financing Liability Noncurrent Revenue interest financing liability noncurrent.
Change In Unrealized Gain Loss On Fair Value Hedging Instruments1 us-gaap/2024 0 0 monetary D C Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.
Cost Of Revenue us-gaap/2024 0 0 monetary D D Cost of Revenue The aggregate cost of goods produced and sold and services rendered during the reporting period.
Interest Expense Nonoperating us-gaap/2024 0 0 monetary D D Interest Expense, Nonoperating Amount of interest expense classified as nonoperating.
Liabilities Current us-gaap/2024 0 0 monetary I C Liabilities, Current Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
Cash And Cash Equivalents At Carrying Value us-gaap/2024 0 0 monetary I D Cash and Cash Equivalents, at Carrying Value Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
Preferred Stock Shares Issued us-gaap/2024 0 0 shares I Preferred Stock, Shares Issued Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.
Share Based Compensation us-gaap/2024 0 0 monetary D D Share-Based Payment Arrangement, Noncash Expense Amount of noncash expense for share-based payment arrangement.
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction us-gaap/2024 0 0 monetary D D Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.
Foreign Currency Transaction Gain Loss Before Tax us-gaap/2024 0 0 monetary D C Gain (Loss), Foreign Currency Transaction, before Tax Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.
Increase Decrease In Inventories us-gaap/2024 0 0 monetary D C Increase (Decrease) in Inventories The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
Increase Decrease In Prepaid Deferred Expense And Other Assets us-gaap/2024 0 0 monetary D C Increase (Decrease) in Prepaid Expense and Other Assets Amount of increase (decrease) in prepaid expenses, and assets classified as other.
Inventory Write Down us-gaap/2024 0 0 monetary D D Inventory Write-down Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.
Nonoperating Income Expense us-gaap/2024 0 0 monetary D C Nonoperating Income (Expense) The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Preferred Stock Value us-gaap/2024 0 0 monetary I C Preferred Stock, Value, Issued Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
Warrants And Rights Outstanding us-gaap/2024 0 0 monetary I C Warrants and Rights Outstanding Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.
Profit Loss us-gaap/2024 0 0 monetary D C Net Income (Loss), Including Portion Attributable to Noncontrolling Interest The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
Accounts Payable And Other Accrued Liabilities Current us-gaap/2024 0 0 monetary I C Accounts Payable and Other Accrued Liabilities, Current Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.
Change In Fair Value Of Share Obligation 0000950170-25-072662 1 0 monetary D D Change In Fair Value Of Share Obligation Change in fair value of share obligation
Net Cash Provided By Used In Operating Activities us-gaap/2024 0 0 monetary D Net Cash Provided by (Used in) Operating Activities Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Increase Decrease In Accrued Liabilities And Other Operating Liabilities us-gaap/2024 0 0 monetary D D Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Amount of increase (decrease) in accrued expenses, and obligations classified as other.
Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment Attributable To Parent us-gaap/2024 0 0 monetary D C Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Tax and Reclassification Adjustment, Attributable to Parent Amount, after tax and reclassification adjustment, of gain (loss) from increase (decrease) in instrument-specific credit risk of financial liability measured under fair value option, attributable to parent.
Operating Expenses us-gaap/2024 0 0 monetary D D Operating Expenses Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
Operating Income Loss us-gaap/2024 0 0 monetary D C Operating Income (Loss) The net result for the period of deducting operating expenses from operating revenues.
Other Liabilities Noncurrent us-gaap/2024 0 0 monetary I C Other Liabilities, Noncurrent Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
Prepaid Expense And Other Assets Current us-gaap/2024 0 0 monetary I D Prepaid Expense and Other Assets, Current Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
Capital Expenditures Incurred But Not Yet Paid us-gaap/2024 0 0 monetary D C Capital Expenditures Incurred but Not yet Paid Future cash outflow to pay for purchases of fixed assets that have occurred.
Restricted Cash us-gaap/2024 0 0 monetary I D Restricted Cash Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
Issuance Of Value Common Stock In Connection With Public Offering Net Of Issuance Costs 0000950170-25-072662 1 0 monetary D C Issuance of Value Common Stock in Connection With Public Offering, Net of Issuance Costs Issuance of value common stock in connection with public offering, net of issuance costs.
Common Stock Value us-gaap/2024 0 0 monetary I C Common Stock, Value, Issued Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
General And Administrative Expense us-gaap/2024 0 0 monetary D D General and Administrative Expense The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
Inventory Net us-gaap/2024 0 0 monetary I D Inventory, Net Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent us-gaap/2024 0 0 monetary D C Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Amount after tax of other comprehensive income (loss) attributable to parent entity.
Research And Development Expense us-gaap/2024 0 0 monetary D D Research and Development Expense Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.
Stock Issued During Period Shares New Issues us-gaap/2024 0 0 shares D Stock Issued During Period, Shares, New Issues Number of new stock issued during the period.
Accounts Payable Current us-gaap/2024 0 0 monetary I C Accounts Payable, Current Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Issuance Of Common Stock For Exercise Of Warrants Shares 0000950170-25-072662 1 0 shares D Issuance Of Common Stock For Exercise Of Warrants Shares Issuance of common stock for exercise of warrants shares.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 0 0 monetary D D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Commitments And Contingencies us-gaap/2024 0 0 monetary I C Commitments and Contingencies Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
Common Stock Shares Authorized us-gaap/2024 0 0 shares I Common Stock, Shares Authorized The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Fair Value Adjustment Of Warrants us-gaap/2024 0 0 monetary D D Fair Value Adjustment of Warrants Amount of expense (income) related to adjustment to fair value of warrant liability.
Increase Decrease In Accounts Payable us-gaap/2024 0 0 monetary D D Increase (Decrease) in Accounts Payable The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
Increase Decrease In Operating Lease Liability us-gaap/2024 0 0 monetary D D Increase (Decrease) in Operating Lease Liability Amount of increase (decrease) in obligation for operating lease.
Interest Paid Net us-gaap/2024 0 0 monetary D C Interest Paid, Excluding Capitalized Interest, Operating Activities Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
Net Cash Provided By Used In Financing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Financing Activities Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Preferred Stock Shares Authorized us-gaap/2024 0 0 shares I Preferred Stock, Shares Authorized The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
Preferred Stock Par Or Stated Value Per Share us-gaap/2024 0 0 perShare I Preferred Stock, Par or Stated Value Per Share Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
Shares Outstanding us-gaap/2024 0 0 shares I Shares, Outstanding Number of shares issued which are neither cancelled nor held in the treasury.
Change In Fair Value Of Rtw Convertible Notes Through Oci 0000950170-25-072662 1 0 monetary D C Change In Fair Value Of RTW Convertible Notes Through Oci Change in fair value of rtw convertible notes through oci.
Proceeds From Equity Line Financing 0000950170-25-072662 1 0 monetary D D Proceeds From Equity Line Financing Proceeds from equity line financing.
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value us-gaap/2024 0 0 monetary D C APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations us-gaap/2024 0 0 monetary I D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Earnings Per Share Basic us-gaap/2024 0 0 perShare D Earnings Per Share, Basic The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
Net Cash Provided By Used In Investing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Investing Activities Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
Other Nonoperating Income Expense us-gaap/2024 0 0 monetary D C Other Nonoperating Income (Expense) Amount of income (expense) related to nonoperating activities, classified as other.
Preferred Stock Shares Outstanding us-gaap/2024 0 0 shares I Preferred Stock, Shares Outstanding Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
Stock Issued During Period Shares Stock Options Exercised us-gaap/2024 0 0 shares D Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Number of share options (or share units) exercised during the current period.
Stock Issued During Period Value New Issues us-gaap/2024 0 0 monetary D C Stock Issued During Period, Value, New Issues Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
Fair Value Adjustment Of Debt 0000950170-25-072662 1 0 monetary D D Fair Value Adjustment of Debt Amount of expense (income) related to adjustment to fair value of debt.
Operating Lease Liability Noncurrent us-gaap/2024 0 0 monetary I C Operating Lease, Liability, Noncurrent Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
Property Plant And Equipment Net us-gaap/2024 0 0 monetary I D Property, Plant and Equipment, Net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
Provision For Doubtful Accounts us-gaap/2024 0 0 monetary D D Accounts Receivable, Credit Loss Expense (Reversal) Amount of expense (reversal of expense) for expected credit loss on accounts receivable.
Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 0 0 shares D Weighted Average Number of Shares Outstanding, Basic Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Change In Fair Value Of Revenue Interest Financing Through Oci 0000950170-25-072662 1 0 monetary D C Change In Fair Value Of Revenue Interest Financing Through OCI Change in fair value of revenue interest financing through OCI

Description
Field Name Field Description
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
custom 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns.
abstract 1 if the tag is not used to represent a numeric fact.
datatype If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag.
iord If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration.
crdr If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL.
tlabel If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here.
doc The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL.

Presentation of Statements

adsh report line stmt inpth rfile tag version plabel negating
0000950170-25-072662 4 8 IS 0 H Operating Expenses us-gaap/2024 Total operating expenses: 0
0000950170-25-072662 4 9 IS 0 H Operating Income Loss us-gaap/2024 Loss from operations 0
0000950170-25-072662 4 11 IS 0 H Interest Expense Nonoperating us-gaap/2024 Interest expense 1
0000950170-25-072662 2 3 BS 0 H Cash And Cash Equivalents At Carrying Value us-gaap/2024 Cash and cash equivalents 0
0000950170-25-072662 2 4 BS 0 H Accounts Receivable Net Current us-gaap/2024 Accounts receivable, net of allowance of doubtful accounts of $6,455 and $6,701, respectively 0
0000950170-25-072662 2 5 BS 0 H Inventory Net us-gaap/2024 Inventory, net 0
0000950170-25-072662 2 6 BS 0 H Prepaid Expense And Other Assets Current us-gaap/2024 Prepaid expenses and other current assets 0
0000950170-25-072662 2 7 BS 0 H Assets Current us-gaap/2024 Total current assets 0
0000950170-25-072662 2 8 BS 0 H Property Plant And Equipment Net us-gaap/2024 Property and equipment, net 0
0000950170-25-072662 2 9 BS 0 H Operating Lease Right Of Use Asset us-gaap/2024 Right-of-use asset 0
0000950170-25-072662 2 10 BS 0 H Other Assets Noncurrent us-gaap/2024 Other long-term assets 0
0000950170-25-072662 2 11 BS 0 H Assets us-gaap/2024 Total assets 0
0000950170-25-072662 2 14 BS 0 H Accounts Payable Current us-gaap/2024 Accounts payable 0
0000950170-25-072662 2 15 BS 0 H Operating Lease Liability Current us-gaap/2024 Current portion of lease liabilities 0
0000950170-25-072662 2 16 BS 0 H Accounts Payable And Other Accrued Liabilities Current us-gaap/2024 Accrued expenses and other current liabilities 0
0000950170-25-072662 2 17 BS 0 H Liabilities Current us-gaap/2024 Total current liabilities 0
0000950170-25-072662 2 18 BS 0 H Convertible Long Term Notes Payable us-gaap/2024 Convertible notes payable 0
0000950170-25-072662 2 19 BS 0 H Warrants And Rights Outstanding us-gaap/2024 Warrant liabilities 0
0000950170-25-072662 2 20 BS 0 H Revenue Interest Financing Liability Noncurrent 0000950170-25-072662 Revenue Interest Financing liability 0
0000950170-25-072662 2 21 BS 0 H Business Combination Contingent Consideration Liability Noncurrent us-gaap/2024 Earn-out liabilities 0
0000950170-25-072662 2 22 BS 0 H Operating Lease Liability Noncurrent us-gaap/2024 Lease liabilities, net of current portion 0
0000950170-25-072662 2 23 BS 0 H Other Liabilities Noncurrent us-gaap/2024 Other liabilities 0
0000950170-25-072662 2 24 BS 0 H Liabilities us-gaap/2024 Total liabilities 0
0000950170-25-072662 2 25 BS 0 H Commitments And Contingencies us-gaap/2024 Commitments and Contingencies (Note 16) 0
0000950170-25-072662 2 27 BS 0 H Preferred Stock Value us-gaap/2024 Preferred stock, $0.0001 par value - 100,000,000 shares authorized as of March 31, 2025; no shares issued and outstanding as of March 31, 2025 and December 31, 2024 0
0000950170-25-072662 2 28 BS 0 H Common Stock Value us-gaap/2024 Common stock, $0.0001 par value - 1,000,000,000 shares authorized as of March 31, 2025; 5,963,549 and 2,710,607 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively 0
0000950170-25-072662 2 29 BS 0 H Additional Paid In Capital us-gaap/2024 Additional paid-in capital 0
0000950170-25-072662 2 30 BS 0 H Accumulated Other Comprehensive Income Loss Net Of Tax us-gaap/2024 Accumulated other comprehensive income 0
0000950170-25-072662 2 31 BS 0 H Retained Earnings Accumulated Deficit us-gaap/2024 Accumulated deficit 0
0000950170-25-072662 2 32 BS 0 H Stockholders Equity us-gaap/2024 Total stockholders' deficit 0
0000950170-25-072662 2 33 BS 0 H Liabilities And Stockholders Equity us-gaap/2024 Total liabilities and stockholders' deficit 0
0000950170-25-072662 3 1 BS 1 H Allowance For Doubtful Accounts Premiums And Other Receivables us-gaap/2024 Allowance of doubtful accounts 0
0000950170-25-072662 3 2 BS 1 H Preferred Stock Par Or Stated Value Per Share us-gaap/2024 Preferred stock, par value 0
0000950170-25-072662 3 3 BS 1 H Preferred Stock Shares Authorized us-gaap/2024 Preferred stock, shares authorized 0
0000950170-25-072662 3 4 BS 1 H Preferred Stock Shares Issued us-gaap/2024 Preferred stock, shares issued 0
0000950170-25-072662 3 5 BS 1 H Preferred Stock Shares Outstanding us-gaap/2024 Preferred stock, shares outstanding 0
0000950170-25-072662 3 6 BS 1 H Common Stock Par Or Stated Value Per Share us-gaap/2024 Common stock, par value 0
0000950170-25-072662 3 7 BS 1 H Common Stock Shares Authorized us-gaap/2024 Common stock, shares authorized 0
0000950170-25-072662 3 8 BS 1 H Common Stock Shares Issued us-gaap/2024 Common stock, shares issued 0
0000950170-25-072662 3 9 BS 1 H Common Stock Shares Outstanding us-gaap/2024 Common stock, shares outstanding 0
0000950170-25-072662 4 1 IS 0 H Revenue From Contract With Customer Excluding Assessed Tax us-gaap/2024 Revenue 0
0000950170-25-072662 4 2 IS 0 H Cost Of Revenue us-gaap/2024 Cost of revenue 0
0000950170-25-072662 4 3 IS 0 H Gross Profit us-gaap/2024 Gross profit 0
0000950170-25-072662 4 5 IS 0 H Selling And Marketing Expense us-gaap/2024 Sales and marketing 0
0000950170-25-072662 4 6 IS 0 H Research And Development Expense us-gaap/2024 Research and development 0
0000950170-25-072662 4 7 IS 0 H General And Administrative Expense us-gaap/2024 General and administrative 0
0000950170-25-072662 4 12 IS 0 H Fair Value Adjustment Of Warrants us-gaap/2024 Changes in fair value of warrants 1
0000950170-25-072662 4 13 IS 0 H Changes In Fair Value Of Debt 0000950170-25-072662 Changes in fair value of debt 1
0000950170-25-072662 4 14 IS 0 H Changes In Fair Value Of Revenue Interest Financing And Pipe Conversion Option 0000950170-25-072662 Changes in fair value of Revenue Interest Financing and PIPE Conversion Option 0
0000950170-25-072662 4 15 IS 0 H Fair Value Adjustment Of Earn Out Liabilities 0000950170-25-072662 Change in fair value of earn-out liabilities 0
0000950170-25-072662 4 16 IS 0 H Other Nonoperating Income Expense us-gaap/2024 Other income (expense), net 0
0000950170-25-072662 4 17 IS 0 H Nonoperating Income Expense us-gaap/2024 Total other income: 0
0000950170-25-072662 4 18 IS 0 H Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest us-gaap/2024 Income before income taxes 0
0000950170-25-072662 4 19 IS 0 H Income Tax Expense Benefit us-gaap/2024 Provision for income taxes 1
0000950170-25-072662 4 20 IS 0 H Net Income Loss us-gaap/2024 Net income 0
0000950170-25-072662 4 21 IS 0 H Earnings Per Share Basic us-gaap/2024 Net income per share - Basic 0
0000950170-25-072662 4 22 IS 0 H Earnings Per Share Diluted us-gaap/2024 Net income per share - diluted 0
0000950170-25-072662 4 23 IS 0 H Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 Weighted-average shares outstanding - Basic 0
0000950170-25-072662 4 24 IS 0 H Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 Weighted-average shares outstanding - diluted 0
0000950170-25-072662 5 7 CI 0 H Net Income Loss us-gaap/2024 Net income 0
0000950170-25-072662 5 9 CI 0 H Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment Attributable To Parent us-gaap/2024 Change in fair value of Revenue Interest Financing due to change in credit risk 0
0000950170-25-072662 5 10 CI 0 H Comprehensive Income Net Of Tax us-gaap/2024 Comprehensive income 0
0000950170-25-072662 6 13 EQ 0 H Stockholders Equity us-gaap/2024 Beginning Balance 0
0000950170-25-072662 6 14 EQ 0 H Shares Outstanding us-gaap/2024 Beginning Balance (in shares) 0
0000950170-25-072662 6 15 EQ 0 H Stock Issued During Period Value Stock Options Exercised us-gaap/2024 Exercise of stock options 0
0000950170-25-072662 6 16 EQ 0 H Stock Issued During Period Shares Stock Options Exercised us-gaap/2024 Exercise of stock options, (in shares) 0
0000950170-25-072662 6 17 EQ 0 H Stock Issued During Period Shares Restricted Stock Award Gross us-gaap/2024 Issuance of common stock in connection with vesting of RSU awards (in shares) 0
0000950170-25-072662 6 18 EQ 0 H Issuance Of Shares Common Stock In Connection With R T W Private Placement Net Of Issuance Costs 0000950170-25-072662 Issuance of common stock in connection with RTW Private Placement, net of issuance costs, Shares 0
0000950170-25-072662 6 19 EQ 0 H Issuance Of Common Stock In Connection With R T W Private Placement Net Of Issuance Costs 0000950170-25-072662 Issuance of common stock in connection with RTW Private Placement, net of issuance costs 0
0000950170-25-072662 6 20 EQ 0 H Issuance Of Shares Common Stock In Connection With Public Offering Net Of Issuance Costs 0000950170-25-072662 Issuance of shares common stock in connection with public offering, net of issuance costs ( in shares) 0
0000950170-25-072662 6 21 EQ 0 H Issuance Of Value Common Stock In Connection With Public Offering Net Of Issuance Costs 0000950170-25-072662 Issuance of value common stock in connection with public offering, net of issuance costs 0
0000950170-25-072662 6 22 EQ 0 H Issuance Of Common Stock For Exercise Of Warrants Shares 0000950170-25-072662 Issuance of common stock for the exercise of Public Warrants (in shares) 0
0000950170-25-072662 6 23 EQ 0 H Stock Issued During Period Value New Issues us-gaap/2024 Stock issued during period value 0
0000950170-25-072662 6 24 EQ 0 H Stock Issued During Period Shares New Issues us-gaap/2024 Stock isssued during the period (in shares) 0
0000950170-25-072662 6 25 EQ 0 H Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value us-gaap/2024 Stock-based compensation expense 0
0000950170-25-072662 6 26 EQ 0 H Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent us-gaap/2024 Other comprehensive income (loss) 0
0000950170-25-072662 6 27 EQ 0 H Net Income Loss us-gaap/2024 Net income 0
0000950170-25-072662 6 28 EQ 0 H Stockholders Equity us-gaap/2024 Ending Balance 0
0000950170-25-072662 6 29 EQ 0 H Shares Outstanding us-gaap/2024 Ending Balance (in shares) 0
0000950170-25-072662 7 8 CF 0 H Profit Loss us-gaap/2024 Net income 0
0000950170-25-072662 7 10 CF 0 H Non Cash Lease Expense 0000950170-25-072662 Non-cash lease expense 0
0000950170-25-072662 7 11 CF 0 H Depreciation And Amortization us-gaap/2024 Depreciation and amortization 0
0000950170-25-072662 7 12 CF 0 H Share Based Compensation us-gaap/2024 Stock-based compensation 0
0000950170-25-072662 7 13 CF 0 H Provision For Doubtful Accounts us-gaap/2024 Provision for uncollectible accounts 0
0000950170-25-072662 7 14 CF 0 H Foreign Currency Transaction Gain Loss Before Tax us-gaap/2024 Unrealized exchange (gain) loss 1
0000950170-25-072662 7 15 CF 0 H Inventory Write Down us-gaap/2024 Provision for inventory 0
0000950170-25-072662 7 16 CF 0 H Change In Fair Value Of Warrant Liabilities 0000950170-25-072662 Change in fair value of warrant liabilities 0
0000950170-25-072662 7 17 CF 0 H Change In Unrealized Gain Loss On Fair Value Hedging Instruments1 us-gaap/2024 Change in fair value of derivative liabilities 1
0000950170-25-072662 7 18 CF 0 H Fair Value Adjustment Of Debt 0000950170-25-072662 Change in fair value of debt 0
0000950170-25-072662 7 19 CF 0 H Changes In Fair Value Of Revenue Interest Financing And Pipe Conversion Option 0000950170-25-072662 Change in fair value of Revenue Interest Financing and PIPE Conversion Option 1
0000950170-25-072662 7 20 CF 0 H Fair Value Adjustment Of Earn Out Liabilities 0000950170-25-072662 Change in fair value of earn-out liabilities 1
0000950170-25-072662 7 21 CF 0 H Change In Fair Value Of Share Obligation 0000950170-25-072662 Change in fair value of Share Obligation 0
0000950170-25-072662 7 22 CF 0 H Non Cash Interest Expense 0000950170-25-072662 Non-cash interest expense 0
0000950170-25-072662 7 23 CF 0 H Amortization Of Issuance Costs Associated With Warrants 0000950170-25-072662 Issuance costs associated with warrants recorded at fair value 0
0000950170-25-072662 7 25 CF 0 H Increase Decrease In Accounts Receivable us-gaap/2024 Accounts receivable 1
0000950170-25-072662 7 26 CF 0 H Increase Decrease In Inventories us-gaap/2024 Inventory 1
0000950170-25-072662 7 27 CF 0 H Increase Decrease In Prepaid Deferred Expense And Other Assets us-gaap/2024 Prepaid expenses, other current and long-term assets 1
0000950170-25-072662 7 28 CF 0 H Increase Decrease In Operating Lease Liability us-gaap/2024 Lease liabilities 0
0000950170-25-072662 7 29 CF 0 H Increase Decrease In Accounts Payable us-gaap/2024 Accounts payable 0
0000950170-25-072662 7 30 CF 0 H Increase Decrease In Accrued Liabilities And Other Operating Liabilities us-gaap/2024 Accrued expenses and other current liabilities 0
0000950170-25-072662 7 31 CF 0 H Net Cash Provided By Used In Operating Activities us-gaap/2024 Net cash used in operating activities 0
0000950170-25-072662 7 33 CF 0 H Payments To Acquire Property Plant And Equipment us-gaap/2024 Purchases of property and equipment 1
0000950170-25-072662 7 34 CF 0 H Net Cash Provided By Used In Investing Activities us-gaap/2024 Net cash used in investing activities 0
0000950170-25-072662 7 36 CF 0 H Proceeds From Issuance Or Sale Of Equity us-gaap/2024 Proceeds from equity offerings, net of issuance costs 0
0000950170-25-072662 7 37 CF 0 H Proceeds From Option And Warrant Exercises 0000950170-25-072662 Proceeds from option and warrant exercises 0
0000950170-25-072662 7 38 CF 0 H Proceeds From Equity Line Financing 0000950170-25-072662 Proceeds from equity line financing 0
0000950170-25-072662 7 39 CF 0 H Net Cash Provided By Used In Financing Activities us-gaap/2024 Net cash provided by financing activities 0
0000950170-25-072662 7 40 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 Net increase (decrease) in cash and cash equivalents and restricted cash 0
0000950170-25-072662 7 41 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations us-gaap/2024 Cash and cash equivalents and restricted cash at beginning of period 0
0000950170-25-072662 7 42 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations us-gaap/2024 Cash and cash equivalents and restricted cash at end of period 0
0000950170-25-072662 7 44 CF 0 H Interest Paid Net us-gaap/2024 Cash paid for interest 0
0000950170-25-072662 7 46 CF 0 H Capital Expenditures Incurred But Not Yet Paid us-gaap/2024 Purchase of property and equipment included in accounts payable 0
0000950170-25-072662 7 47 CF 0 H Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction us-gaap/2024 Deferred financing costs in accounts payable and accrued expenses 0
0000950170-25-072662 7 48 CF 0 H Change In Fair Value Of Rtw Convertible Notes Through Oci 0000950170-25-072662 Change in fair value of RTW Convertible Notes through OCI 0
0000950170-25-072662 7 49 CF 0 H Change In Fair Value Of Revenue Interest Financing Through Oci 0000950170-25-072662 Change in fair value of Revenue Interest Financing through OCI 0
0000950170-25-072662 8 1 UN 0 H Cash And Cash Equivalents At Carrying Value us-gaap/2024 Cash and cash equivalents 0
0000950170-25-072662 8 2 UN 0 H Restricted Cash us-gaap/2024 Restricted cash included in other long-term assets 0
0000950170-25-072662 8 4 UN 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Cash and cash equivalents and restricted cash shown in the statement of cash flows 0

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
report Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site.
line Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived.
stmt The financial statement location to which the value of the “report” field pertains.
inpth Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700.
rfile The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file.
tag The tag chosen by the filer for this line item.
version The taxonomy identifier if the tag is a standard tag, otherwise adsh.
plabel The text presented on the line item, also known as a “preferred” label.
negating Flag to indicate whether the plabel is negating.